Export 35 results:
Author Title [ Type(Asc)] Year
Filters: Author is Costa, E.  [Clear All Filters]
Journal Article
Pellegrino, R. M., Coutinho, M., D'Ascola, D., Lopes, A. M., et al. (2012). Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form. British Journal of Haematology, 158(5), 668 - 672.
Costa, E., Pereira, B. J. G., Rocha-Pereira, P., Rocha, S., et al. (2008). Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. American Journal of Nephrology, 28(4), 677 - 683.
Teixeira, A. M., Garrido, P., Santos, P., Alves, R., et al. (2010). Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Renal Failure, 32(9), 1073 - 1080.
Rocha, S., Rebelo, I., Costa, E., Catarino, C., et al. (2005). Protein deficiency balance as a predictor of clinical outcome in hereditary spherocytosis. European Journal of Haematology, 74(5), 374 - 380.
Ribeiro, S., Faria, M. D. S., Silva, G., Nascimento, H., et al. (2012). Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodialysis International, 16(4), 481 - 490.
Pereira, R., Costa, E., Gonçalves, M., Miranda, V., et al. (2010). Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodialysis International, 14(3), 295 - 301.
Costa, E., Rocha, S., Rocha-Pereira, P., Nascimento, H., et al. (2008). Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. American Journal of Nephrology, 28(6), 935 - 940.
Costa, E., Coimbra, J., Catarino, C., Ribeiro, S., et al. (2012). Major determinants of BMP-2 serum levels in hemodialysis patients. Renal Failure, 34(10), 1355 - 1358.
Ribeiro, S., Do Sameiro Faria, M., Mascarenhas-Melo, F., Freitas, I., et al. (2012). Main determinants of PON1 activity in hemodialysis patients. American Journal of Nephrology, 36(4), 317 - 323.
Alexandre, N., Amorim, I., Caseiro, A. R., Pereira, T., et al. (2016). Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model. International Journal of Pharmaceutics, 513(1-2), 332 - 346.
Alexandre, N., Amorim, I., Caseiro, A. R., Pereira, T., et al. (2017). Long term performance evaluation of small-diameter vascular grafts based on polyvinyl alcohol hydrogel and dextran and MSCs-based therapies using the ovine pre-clinical animal model. International Journal of Pharmaceutics, 523(2), 515 - 530.
Rocha, S., Costa, E., Coimbra, S., Nascimento, H., et al. (2009). Linkage of cytosolic peroxiredoxin 2 to erythrocyte membrane imposed by hydrogen peroxide-induced oxidative stress. Blood Cells, Molecules, and Diseases, 43(1), 68 - 73.
Costa, E., Lima, M., Alves, J. M., Rocha, S., et al. (2008). Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. Journal of Clinical Immunology, 28(3), 268 - 275.
Rodrigues, C., Vieira, E., Santos, R., de Carvalho, J., et al. (2012). Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. Blood Cells, Molecules, and Diseases, 48(3), 166 - 172.
Costa, E., Lima, M., Rocha, S., Rocha-Pereira, P., et al. (2008). IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. Blood Cells, Molecules, and Diseases, 41(1), 134 - 135.
Rocha, S., Costa, E., Ferreira, F., Cleto, E., et al. (2010). Hereditary spherocytosis and the (TA)nTAA polymorphism of UGT1A1 gene promoter region-A comparison of the bilirubin plasmatic levels in the different clinical forms. Blood Cells, Molecules, and Diseases, 44(2), 117 - 119.
Costa, E., Swinkels, D. W., Laarakkers, C. M., Rocha-Pereira, P., et al. (2009). Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematologica, 122(4), 226 - 229.
Rocha, S., Costa, E., Catarino, C., Belo, L., et al. (2005). Erythropoietin levels in the different clinical forms of hereditary spherocytosis. British Journal of Haematology, 131(4), 534 - 542.
Rocha, S., Costa, E., Rocha-Pereira, P., Ferreira, F., et al. (2011). Erythropoiesis versus inflammation in Hereditary Spherocytosis clinical outcome. Clinical Biochemistry, 44(13), 1137 - 1143.
Rocha, S., Costa, E., Rocha-Pereira, P., Ferreira, F., et al. (2010). Erythrocyte membrane protein destabilization versus clinical outcome in 160 Portuguese Hereditary Spherocytosis patients. British Journal of Haematology, 149(5), 785 - 794.
Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2009). Effect of hemodialysis procedure in prohepcidin serum levels in regular hemodialysis patients. Clinical Nephrology, 71(2), 233 - 235.
Costa, E., Rocha, S., Rocha-Pereira, P., Reis, F., et al. (2008). DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis. Acta Haematologica, 120(1), 11 - 13.
Costa, E., Rocha, S., Rocha-Pereira, P., Castro, E., et al. (2008). Cross-talk between inflammation, coagulation/fibrinolysis and vascular access in hemodialysis patients. Journal of Vascular Access, 9(4), 248 - 253.
Rocha, S., Costa, E., Rocha-Pereira, P., Ferreira, F., et al. (2011). Complementary markers for the clinical severity classification of hereditary spherocytosis in unsplenectomized patients. Blood Cells, Molecules, and Diseases, 46(2), 166 - 170.
Ribeiro, S., Nascimento, H., Borges, A., Faria, M. D. S., et al. (2012). Comparison of Bio-Plex measurements with standard techniques. Clinical Chemistry and Laboratory Medicine, 50(2), 399 - 402.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@ibmc.up.pt | © copyright 2010 ibmc